Cytomx therapeutics, inc. (CTMX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net income (loss)

-75,909

-102,238

-99,015

-98,749

-83,235

-84,604

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-57,753

-62,168

-51,128

-58,900

-56,354

-53,562

-45,192

-35,374

0

0

0

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Loss/(gain) on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Amortization of intangible assets

146

146

146

146

146

146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

0

1,626

-

1,731

1,697

1,773

1,733

1,572

1,436

1,293

1,206

0

0

0

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

80

0

0

0

Accretion of discounts on investments

1,642

2,228

2,550

2,465

2,153

1,701

1,135

609

93

-371

-798

-1,182

-1,515

-1,662

-1,626

-1,568

-1,412

-1,186

0

0

0

Stock-based compensation expense

17,921

19,100

19,605

19,675

18,382

16,878

15,012

13,379

12,228

11,287

11,159

11,099

10,480

10,095

9,394

8,018

6,173

3,986

0

0

0

Issuance of common stock in connection with UCSB sublicense fee

-

-

-

-

-

-

-

-

-

-

-

-

-

159

0

0

0

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

-

-513

7

26

4

6

0

0

0

-

-

-

-

Changes in operating assets and liabilities
Accounts receivable

129,966

-84

-49

-15,133

-37

-10,042

-127

24,979

-132

7,980

-57

-127

-103

1,787

-1,336

-1,432

-1,185

-1,131

0

0

0

Related party accounts receivable

-

-

-

-

-

-

-

-

-

-154

-139

-86

-103

-218

0

0

0

-

0

0

0

Prepaid expenses and other current assets

13,697

-2,074

1,168

1,301

2,963

4,899

3,042

1,651

1,356

456

447

1,168

680

1,597

3,197

1,924

2,220

1,491

0

0

0

Other assets

0

-

-

-

-

20

-1,696

-1,865

-1,378

-1,618

2,845

2,972

2,444

2,609

-145

-174

-161

-128

0

0

0

Accounts payable

-5,484

-374

-2,382

693

4,308

261

3,849

-2,949

1,499

-2,441

2,329

5,050

-1,306

1,765

-1,864

588

3,757

2,944

0

0

0

Accrued liabilities, income tax payable and other long-term liabilities

-8,734

-12,724

-7,823

-6,574

17,083

24,833

15,585

20,693

12,111

9,157

0

0

0

-

-

-

-

-

-

-

-

Accrued liabilities and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

3,953

0

0

0

-

-

-

-

Deferred revenue

62,136

-47,741

-50,557

-52,318

-53,522

-38,195

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

0

23,535

-

30,868

32,370

3,601

-6,130

0

0

0

Net cash used in operating activities

-151,188

-140,480

-139,743

-121,975

-99,938

-75,521

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-15,578

-

-12,137

-5,721

-27,586

-27,415

0

0

0

Purchases of property and equipment

2,711

3,497

3,913

4,335

4,872

3,788

2,903

1,910

1,366

1,559

1,927

2,733

2,793

2,176

1,756

1,256

1,666

1,594

0

0

0

Purchases of short-term investments

157,382

174,992

192,390

206,614

218,786

204,601

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

260,841

258,190

238,989

211,945

234,361

214,315

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

0

0

127,767

-

242,865

258,878

232,957

250,901

0

0

0

Maturities of short-term investments

-

-

-

-

-

-

-

-

-

-

0

0

162,000

-

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

100,748

79,701

42,686

996

10,703

5,926

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

74,430

0

0

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

31,492

-

-47,438

-57,451

-64,940

-130,562

0

0

0

Proceeds from employee stock purchase plan and exercise of stock options

3,319

1,627

1,950

2,867

2,891

5,028

5,426

5,606

5,550

3,839

3,218

2,309

1,773

930

0

0

0

-

-

-

-

Repayment of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,067

0

0

0

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

12

0

0

0

-

-

-

-

Net cash provided by financing activities

3,319

1,627

1,950

137,463

137,487

139,624

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-47,121

-59,152

-95,107

16,484

48,252

70,029

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

1,851

-

83,142

79,709

152,604

153,403

0

0

0

Net increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

0

0

17,765

-

23,567

16,537

60,078

-4,574

0

0

0

Supplemental disclosures of cash flow information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Supplemental disclosures of noncash investing and financing items:
Purchases of property and equipment in accounts payable and accrued liabilities

-

428

1,087

613

881

1,027

0

0

0

-

-

-

677

473

44

176

-337

100

0

0

0

Right of use assets obtained in exchange for operating lease obligations

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion to redemption value and cumulative dividends on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,705

0

0

0